Sequent Scientific is India's leading animal health company, with presence in 5+ continents across 100 countries. Sequent Scientific Limited provides a wide-ranging portfolio of animal health products, including Finished Dose Formulations, APIs, as well as analytical services to the pharmaceutical and life sciences industries. SeQuent Scientific Limited is India's largest and amongst the 'Top 20' global animal health companies, backed by global investment firm 'The Carlyle Group' as the promoter.
Sequent Scientific Ltd. is a leading manufacturer and exporter of specialized quality formulations aimed at fulfilling the diverse demands of the pharmaceutical industry. It manufactures formulations belonging to the anthelmintic and anti-parasitic segments. It was incorporated in 1985 with its headquarters in Mumbai. The company operates through 2 business segments: Formulation and API.
SeQuent has seven manufacturing facilities based in India, Spain, Brazil, and Turkey with approvals from international regulatory bodies, including USFDA, EUGMP, WHO, TGA, etc. The company has 8 manufacturing facilities across Europe, Turkey, Brazil & India with the Vizag site being India's only USFDA approved dedicated veterinary API facility. SeQuent's seven manufacturing facilities, located in India, Spain, Brazil, and Turkey, have obtained approvals from leading global regulatory bodies such as US FDA, EUGMP, WHO, and TGA, among others.
The company's operations span across multiple continents, with operations in over 90 countries with 7 manufacturing facilities, serving consumers worldwide. SeQuent offers a comprehensive portfolio of finished drug formulations, active pharmaceutical ingredients along with analytical services, which address the needs of the global animal health sector.
Sequent Scientific's formulations segment accounts for a sizable amount of its sales, due to a strong market presence in regulated regions such as Europe and rising markets like India. Key areas include pain management, parasite control, antibiotics, and animal gut health solutions. This segment is supported by multiple manufacturing facilities and four R&D centres. The formulations business thrived with nearly 20% growth, while the API segment showed signs of recovery, bolstered by strategic initiatives and a focus on operational efficiency.
The APIs business serves animal health firms worldwide, with two manufacturing facilities and an R&D centre. Sequent's focus on efficiency has increased profits, particularly through Project Pragati, which has improved operational performance. Approximately two-thirds of API sales come from regulated markets, and recent approvals in key areas, such as WHO prequalification, are creating new business opportunities.
Alivira is one of the world's leading producers of Animal Health APIs, and it is gradually emerging as a powerhouse in the global animal health business. The brand is strengthened by best-in-class manufacturing capacities, robust product portfolio, wide market presence, and cutting-edge R&D capabilities. Alivira has state-of-the-art API manufacturing facility at Vizag with a present production of 1,000 MT with scalable capacities.
Sequent Scientific Limited reported a net profit of ₹9.32 Crore for Q4 FY25, a significant turnaround from a loss last year. For FY25, net profit reached ₹44.3 Crore, with revenue growing 13.3% year-on-year to ₹1,551.4 Crore, reflecting improved operational efficiency.
Net profit of Sequent Scientific reported to ₹9.32 Crore in the quarter ended March 2025, as against net loss of ₹0.92 Crore during the previous quarter ended March 2024. Sales rose 11.21% to ₹401.70 Crore in the quarter ended March 2025, as against ₹361.20 Crore during the previous quarter ended March 2024.
For the full year, net profit reported to ₹21.88 Crore in the year ended March 2025, as against net loss of ₹35.88 Crore during the previous year ended March 2024. Sales rose 13.26% to ₹1,551.37 Crore in the year ended March 2025, as against ₹1,369.73 Crore during the previous year ended March 2024.
- Revenue (FY25): ₹1,551.37 Crore
- Net Profit (FY25): ₹21.88 Crore
- Q4 FY25 Revenue: ₹401.70 Crore
- Q4 FY25 Net Profit: ₹9.32 Crore
- Market Cap (as of July 2025): ₹4,800 Crore
By relocating production from Germany to Turkey, SeQuent has optimized its asset utilization and achieved better cost efficiency, with commercial operations in Turkey expected to resume by FY26. Cost-cutting and operational efficiency initiatives in LATAM and Turkey contributed to consistent EBITDA margins, which helped to offset economic headwinds.
Despite challenges with cash flow conversion due to high inventory levels, management remains optimistic about future growth, particularly with the upcoming merger with Viyash Life Sciences, which is expected to enhance R&D capabilities and operational performance. The company is also expanding its companion animal health segment and pursuing opportunities in the CDMO space, positioning itself for sustained growth and improved margins.
Carlyle-backed animal health company SeQuent Scientific and Viyash Life Sciences have announced a ₹8,000 Crore merger to create a platform, which will be one of India's largest in animal pharmaceuticals. The combined entity will have access to global markets (over 150 countries) with strong R&D, intellectual property, and product development capabilities, and 16 state-of-the-art manufacturing facilities.
The entity will have a 5x higher R&D talent pool and 9x more US FDA approved manufacturing facilities, which will form a strong operating backbone to better serve its customer base. SeQuent intends to establish a leadership position in the animal health market by combining Viyash's R&D and production capabilities. Viyash brings a strong infrastructure, including nine USFDA-approved manufacturing sites, which is expected to boost SeQuent's production and R&D capabilities.
Under the veterinary segment, the company continues to supply its products to eight out of the top SSL's customer profile consists of global major animal health companies including Zoetis Inc, Merck Animal Health, Bayer Animal Health, Virbac, Ceva, Vetoquinol, Boehringer Ingelheim, etc. By virtue of its large customer base, the company's customer concentration is moderate thereby mitigating the risk of order volatility. Established relationships with a wide base of customers coupled with the regular addition of customers have supported the healthy revenue growth of the company over the years.
Sequent Scientific Ltd share price was ₹191.75 at close on May 30, 2025. Sequent Scientific Ltd share price was down by 1.41% from the previous closing price of ₹194.50. The Sequent Scientific Ltd's 52-week high share price is ₹240.90 and 52-week low share price is ₹91.85.
Last 3 Years: Sequent Scientific Ltd share price moved up by 76.16% on BSE. Promoter holding in Sequent Scientific Ltd has gone down to 52.61% as of March 2025 from 52.78% as of June 2024.
The company's stock trades on both NSE and BSE, with Sequent Scientific Ltd.'s shares are listed on the Bombay Stock Exchange with the code 512529, and on the National Stock Exchange with the code SEQUENT. With strong operational improvements and strategic initiatives underway, Sequent Scientific remains positioned as a key player in the global animal health market.
